Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus
Randomized trial
Abstract
In a randomized, placebo-controlled study, bitter melon (Momordica charantia) extract as adjuvant treatment for 12 weeks significantly reduced fasting glucose in patients with type 2 diabetes, with no serious adverse events, supporting its glucose-lowering use.
Referenced for these plants
How to cite
Kim, S.K., Jung, J., Jung, J.H., Yoon, N. and others (2020) 'Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus', Complementary Therapies in Medicine, 52, pp. 102524. doi:10.1016/j.ctim.2020.102524
This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.